Interim 2023/2024 season influenza vaccine effectiveness in primary and secondary care in the United Kingdom

Whitaker, Heather and Findlay, Beth and Zitha, Jana and Goudie, Rosalind and Hassell, Katie and Evans, Josie and Kalapotharakou, Panoraia and Agrawal, Utkarsh and Kele, Beatrix and Hamilton, Mark and Moore, Catherine and Byford, Rachel and Stowe, Julia and Robertson, Chris and Couzens, Anastasia and Jamie, Gavin and Hoschler, Katja and Pheasant, Kathleen and Button, Elizabeth and Quinot, Catherine and Jones, Tim and Anand, Sneha and Watson, Conall and Andrews, Nick and de Lusignan, Simon and Zambon, Maria and Williams, Christopher and Cottrell, Simon and Marsh, Kimberly and McMenamin, Jim and Lopez Bernal, Jamie (2024) Interim 2023/2024 season influenza vaccine effectiveness in primary and secondary care in the United Kingdom. Influenza and Other Respiratory Viruses, 18 (5). e13284. ISSN 1750-2640 (https://doi.org/10.1111/irv.13284)

[thumbnail of Whitaker-etal-IORV-2024-Interim-2023-2024-season-influenza-vaccine-effectiveness-in-primary-and-secondary-care]
Preview
Text. Filename: Whitaker-etal-IORV-2024-Interim-2023-2024-season-influenza-vaccine-effectiveness-in-primary-and-secondary-care.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (235kB)| Preview

Abstract

Background: We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England. Methods: A test negative design was used to estimate vaccine effectiveness. Results: Estimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2–17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18–64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over. Conclusions: During a period of co‐circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.